Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer
Ludovic Fournel, Zherui Wu, Nicolas Städler et al. · Cancer Letters · 2019
Cited by 249 works. doi:10.1016/j.canlet.2019.08.005
Authors
- Ludovic Fournel
- Zherui Wu
- Nicolas Städler
- Diane Damotte
- Filippo Lococo
- G. Boulle
- Antonio Bobbio
- Philippe Icard
- Jean Trédaniel
- Marco Alifano
- Patricia Forgez
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- PD-L1 Expression in Triple-Negative Breast Cancer
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- Lung Cancer Statistics